Joaquin Duato is Chairman and Chief Executive Officer of Johnson & Johnson, leading one of the world’s largest healthcare companies across pharmaceuticals and medical technology. Since assuming the CEO role in January 2022 and Chairman in January 2023, he has overseen a significant strategic refocus of the company, including the separation of Consumer Health and a sharpened emphasis on science-driven pharmaceuticals and advanced medtech. Under his leadership, Johnson & Johnson has strengthened its position in oncology by prioritizing areas of high unmet need, advancing complex modalities such as cell and gene therapies, and reinforcing global development and manufacturing capabilities to support innovation at scale.
During Duato’s tenure, Johnson & Johnson has continued to invest heavily in oncology research and development, clinical execution, and global access, while improving operational discipline across its pharmaceutical portfolio. His leadership has emphasized data-enabled development, supply-chain resilience, and long-term platform building rather than short-term expansion, supporting the company’s sustained role in cancer research, treatment innovation, and multidisciplinary care.
Duato has spent more than three decades at Johnson & Johnson, holding senior leadership roles across multiple geographies and business segments. Prior to becoming CEO, he served as Vice Chairman of the Executive Committee, with oversight of pharmaceuticals, consumer health, technology, and global supply chain operations. In 2023, he was awarded Spain’s Order of Civil Merit (Commander by Number) in recognition of his leadership and international contributions.
The 100 CEOs featured here reflect the diversity and complexity of modern oncology leadership. In 2025, some lead the world’s largest cancer institutions; others guide specialized societies or emerging innovators. What unites them is responsibility: for millions of patients, for the integrity of science, and for the future direction of cancer care globally.
This list is not a celebration of power, but a recognition of stewardship, accountability, and impact – and of the leaders whose choices continue to shape the fight against cancer. For the many deserving individuals not mentioned in this list, we will continue to acknowledge, honor and elevate your voices in our daily publications from across the world.
See the full list of The 100 Influential CEOs in Oncology in 2025 and stay tuned for other special category nominations
